Skip to main content

Table 1 Comparison of clinical features between the three groups

From: Short-chain fatty acid-butyric acid ameliorates granulosa cells inflammation through regulating METTL3-mediated N6-methyladenosine modification of FOSL2 in polycystic ovarian syndrome

 

Control (n = 6)

FAT (n = 6)

HA (n = 6)

Age (year)

27.50 ± 2.59

27.50 ± 2.88

28.83 ± 3.76

BMI (kg/m2)

20.26 ± 2.38

27.16 ± 2.20A

24.42 ± 3.56

AMH (ng/ml)

2.77 ± 0.59

5.66 ± 0.64A

5.47 ± 1.05B

FSH (U/L)

7.26 ± 2.05

5.97 ± 1.42A

5.74 ± 1.04A

LH (U/L)

2.52 ± 1.27

4.34 ± 1.93

11.46 ± 2.39

T (ng/dL)

44.91 ± 9.36

45.25 ± 20.80

104.10 ± 26.61B,C

E2 (pg/ml)

49.17 ± 29.11

50.67 ± 27.15

40.67 ± 7.55

TNF-α (pg/ml)

78.48 ± 12.93

203.01 ± 29.55A

119.50 ± 4.48B,C

IL-6 (pg/ml)

21.42 ± 6.87

93.65 ± 8.65A

49.18 ± 5.82B,C

  1. AP < 0.05 for control versus FAT group
  2. BP < 0.05 for control versus HA group
  3. CP < 0.05 for FAT versus HA group